Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection
about
Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infectionTreatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacinRationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulationLiposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.Niosomes of ascorbic acid and α-tocopherol in the cerebral ischemia-reperfusion model in male ratsNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.A mathematical relationship for hydromorphone loading into liposomes with trans-membrane ammonium sulfate gradients.Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosaMechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.Enhanced intracellular delivery and antibacterial efficacy of enrofloxacin-loaded docosanoic acid solid lipid nanoparticles against intracellular SalmonellaNanotechnology-Based Approach in Tuberculosis Treatment.Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances.Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.Factors pivotal for designing of nanoantimicrobials: an exposition.Structure activity relationship, acute toxicity and cytotoxicity of antimycobacterial neolignan analogues.Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery.Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation.In vitrouptake and antimycobacterial activity of liposomal usnic acid formulation.Synergistic effect of phospholipid-based liposomes and propylthiouracil on U-937 cell growth.Targeted antibiotic delivery using low temperature-sensitive liposomes and magnetic resonance-guided high-intensity focused ultrasound hyperthermia.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Release Studies on Ciprofloxacin Loaded Non-ionic Surfactant Vesicles.In vitro activity of Pheroid vesicles containing antibiotics against Plasmodium falciparum.Quantitative structure-property relationship modeling of remote liposome loading of drugs.Liposomes as an ocular delivery system of fluconazole: in-vitro studies.Temperature-sensitive liposomal ciprofloxacin for the treatment of biofilm on infected metal implants using alternating magnetic fields.Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
P2860
Q28344603-80C870AF-565D-41C9-813F-943FABE31742Q28379298-B8D27C61-B89B-4B2E-AE04-A2AE67DD9C8EQ33690206-51555607-C9D4-47C2-9C33-18E9D2C3610CQ33690455-5D63268D-46AB-4156-9BFD-CAED791F29A1Q33797873-92734987-45B6-4EC5-8BCC-E2EA3C190CF2Q33906751-DB8F7E98-ECC9-4BA2-A1DA-5E5DB07B8E20Q33982098-AC26E037-AF4F-4D3E-BE04-415C132C0739Q34057550-0DBE1641-2876-460D-BFF4-87FDBB8F4BC6Q34177003-8DA8BDB5-B0C3-4438-A762-FC135591DC1BQ34534023-4D301F8A-8371-4098-9862-D28E550BE2FEQ34557961-69BB924E-C93A-4C24-BDF8-813646EF18EDQ35136593-A4FFCD10-C5E0-4FB1-AFC9-277EA325F423Q36669842-19A50B5E-27DE-4FCF-A203-28ACC49D9C3AQ36782265-46D48563-94B2-4322-B4BB-1FBDDFF0BDCCQ37598577-CCCB44B3-E401-4064-A103-A5EDF95F9EB6Q37624974-9CB5611D-EABC-48CD-B838-182658BC01E9Q37805491-600EBBE5-FA00-4573-A9E8-54DAF876A8BAQ38442447-D4B7EF64-7261-45BF-B009-69ED5026259BQ38938501-2194E9CA-9185-46A9-B5B8-0004D01B8BC1Q39250173-8692599C-4F4A-4B62-9715-11424102939CQ39531716-597A73E7-D095-4220-9E4C-A4860103079FQ39672174-AD2F6403-3127-45DF-89F8-A8F3C9314F89Q39839885-6E47278F-D559-4356-8946-FBCE5F86D9C7Q39839890-FC751B0B-6D8D-459C-A2B0-81116C7E1C33Q40333885-AA0C0A1B-8F95-4767-BEB0-C9F7B7F802F8Q40785876-29FC1B1A-B022-42FF-8750-DBF73A44673CQ40974806-347CF589-AD6F-4365-AB86-E7702057ADDAQ41125275-98DD4AC5-7242-45F4-A9F7-A5B0BD1FB382Q41928024-BE219AD7-4E82-4EF5-9D31-B55F11B958AEQ42322486-A3ADB7B5-A165-4532-B40C-3336EECB0737Q43291837-4D0D9738-B740-47FB-90A8-2CAE44855266Q51745320-FDE30103-2081-45E1-AED7-32B00BE7F9E4Q53123885-B186E079-949C-4F10-A4E0-F2F094785614
P2860
Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Formulation and efficacy of li ...... Mycobacterium avium infection
@ast
Formulation and efficacy of li ...... Mycobacterium avium infection
@en
Formulation and efficacy of li ...... Mycobacterium avium infection
@nl
type
label
Formulation and efficacy of li ...... Mycobacterium avium infection
@ast
Formulation and efficacy of li ...... Mycobacterium avium infection
@en
Formulation and efficacy of li ...... Mycobacterium avium infection
@nl
prefLabel
Formulation and efficacy of li ...... Mycobacterium avium infection
@ast
Formulation and efficacy of li ...... Mycobacterium avium infection
@en
Formulation and efficacy of li ...... Mycobacterium avium infection
@nl
P2093
P2860
P356
P1476
Formulation and efficacy of li ...... Mycobacterium avium infection
@en
P2093
P2860
P304
P356
10.1128/AAC.39.9.2104
P407
P577
1995-09-01T00:00:00Z